SRR12475121
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.470
- PANCREAS_BETA_CELLS+0.370
- TGF_BETA_SIGNALING+0.350
- HEME_METABOLISM+0.340
- ANDROGEN_RESPONSE+0.330
- UV_RESPONSE_DN+0.290
- COMPLEMENT+0.270
- BILE_ACID_METABOLISM+0.230
- PI3K_AKT_MTOR_SIGNALING+0.200
- FATTY_ACID_METABOLISM+0.180
Top 10 suppressed
- MYC_TARGETS_V2-0.760
- E2F_TARGETS-0.630
- MYC_TARGETS_V1-0.600
- G2M_CHECKPOINT-0.540
- DNA_REPAIR-0.400
- WNT_BETA_CATENIN_SIGNALING-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- ANGIOGENESIS-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.300
- MTORC1_SIGNALING-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12475139 | — | — | 0.927 |
| 2 | 0429cf04-6e5c-41dd-b4a9-4f7ad15d15bc | — | — | 0.881 |
| 3 | SRR12475115 | — | — | 0.869 |
| 4 | 996d8c98-529a-4438-9db5-d49ff575af45 | — | — | 0.861 |
| 5 | SRR17866835 | — | — | 0.859 |
| 6 | SRR12475148 | — | — | 0.843 |
| 7 | SRR12475112 | — | — | 0.837 |
| 8 | SRR23036898 | — | — | 0.836 |
| 9 | SRR17866825 | — | — | 0.831 |
| 10 | BS_GCA4GET3 | low-grade glioma | — | 0.820 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.470 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.370 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.340 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.180 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.160 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.140 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |